Guard Therapeutics secures conditional Nasdaq First North listing for reverse acquisition

Guard Therapeutics received conditional approval from Nasdaq Stockholm to maintain its listing on the First North Growth Market following its planned reverse acquisition of Disruptive Pharma. The approval is contingent upon the company meeting standard exchange requirements prior to the transaction's completion.